Risk of serotonin syndrome in acutely ill patients receiving linezolid and opioids concomitantly: a retrospective cohort study.

Autor:	Mitwally H; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Saad MO; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Alkhiyami D; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Fahmi AM; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Mahmoud S; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Hmoud EA; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Enany RE; Pharmacy Department, Al-Wakra Hospital, Hamad Medical Corporation, Qatar., Younis H; Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Qatar., Mohammed S; Pharmacy Department, Hamad Medical Corporation, Qatar., Rouf PA; Pharmacy Department, Hamad Medical Corporation, Qatar., Thomas B; Pharmacy Department, Hamad Medical Corporation, Qatar., Hail MA; Pharmacy Department, Hamad Medical Corporation, Qatar.
Jazyk:	angličtina
Zdroj:	IJID Regions (Online) [IJID Reg] 2022 Sep 24; Vol. 5, pp. 137-140. Date of Electronic Publication: 2022 Sep 24 (Print Publication: 2022).
DOI:	10.1016/j.ijregi.2022.09.008
Abstrakt:	Introduction: Linezolid is an oxazolidinone antibiotic with a reversible, non-selective, monoamine oxidase inhibitory effect. Combining linezolid with serotonergic agents may increase serotonin syndrome (SS) risk.Linezolid is recommended in patients with suspected or confirmed resistant Gram-positive bacterial infections, especially if vancomycin cannot be used. However, it is unclear whether co-administration of linezolid with opioids increases the risk of serotonin syndrome. Research Objective: To establish whether combining linezolid with opioids will increase the incidence of SS in acutely ill patients. Methods: This was a retrospective observational study. All adult patients who were admitted and received linezolid between March and September 2020 were included in the study. The primary outcome was the prevalence of SS, as defined by Hunter's criteria. Results: The study included 106 patients, most whom were males (91.5%). More than half of the cohort (56.6%) received a concomitant opioid agent. Morphine and fentanyl were the most prescribed opioids (37.7% and 34%, respectively). Among patients who received opioids, only one patient (1.6%) had spontaneous clonus. However, this patient developed spontaneous clonus post cardiac arrest, which made an association with the linezolid-opioids combination less likely. Conclusion: In this study, the incidence of SS was low in acutely ill patients who received concomitant linezolid and opioids. However, larger prospective studies are required to confirm this finding. Competing Interests: The authors declare that they have no conflicts of interest to disclose. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu